Indeed, through its partial inhibition of interleukin-2-inducible kinase (ITK), the drug reduces the absolute counts of both CD4+ and CD8+ T cells [15,16] but interestingly may improve the ex vivo cytotoxic function of the latter against CLL cells [17]. Here, CD8A is linked to B-cell chronic lymphocytic leukemia.